Literature DB >> 2846102

Postmarketing surveillance of enalapril. II: Investigation of the potential role of enalapril in deaths with renal failure.

C J Speirs1, C T Dollery, W H Inman, N S Rawson, L V Wilton.   

Abstract

The possibility that enalapril might damage renal function was investigated in 1098 deaths recorded in a prescription-event monitoring study. Case notes for 913 patients were examined. In seventy five there was a rise in the urea or creatinine concentration of 50% or more above pretreatment values. Enalapril appeared to have contributed to a decline in renal function and subsequent death in 10 of these patients. Several characteristics were identified among these patients, including old age, the use of high dose or potassium sparing diuretics, and pre-existing renal disease. Adding a non-steroidal anti-inflammatory drug was also associated with a deterioration in patients with previously stable renal function. No death was encountered of a patient with uncomplicated hypertension. Enalapril infrequently contributed to a substantial decline in renal function in certain vulnerable patients, especially those receiving other drugs known to be capable of adversely affecting renal function. Awareness of the characteristics of these patients and of their concomitant treatment may serve to reduce the risk.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846102      PMCID: PMC1834596          DOI: 10.1136/bmj.297.6652.830

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  10 in total

1.  Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity.

Authors:  J R Wilson; J S Schwartz; M S Sutton; N Ferraro; L N Horowitz; N Reichek; M E Josephson
Journal:  J Am Coll Cardiol       Date:  1983-09       Impact factor: 24.094

2.  Renal response to angiotensin-converting enzyme inhibition.

Authors:  N K Hollenberg
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

3.  Captopril and renal autoregulation.

Authors:  W B Blythe
Journal:  N Engl J Med       Date:  1983-02-17       Impact factor: 91.245

4.  Renal failure associated with captopril.

Authors:  M J Schreiber; L S Fang
Journal:  JAMA       Date:  1983-07-01       Impact factor: 56.272

5.  Postmarketing surveillance of enalapril. I: Results of prescription-event monitoring.

Authors:  W H Inman; N S Rawson; L V Wilton; G L Pearce; C J Speirs
Journal:  BMJ       Date:  1988-10-01

6.  Delayed elimination of triamterene and its active metabolite in chronic renal failure.

Authors:  H Knauf; W Möhrke; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Limitation on the use of amiloride in early renal failure.

Authors:  H Knauf; K Reuter; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Spironolactone-associated aggravation of renal functional impairment.

Authors:  T J Neale; K L Lynn; R R Bailey
Journal:  N Z Med J       Date:  1976-03-10

9.  Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice.

Authors:  W D Cooper; D Sheldon; D Brown; G R Kimber; V L Isitt; W J Currie
Journal:  J R Coll Gen Pract       Date:  1987-08

10.  Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects.

Authors:  L Favre; P Glasson; M B Vallotton
Journal:  Ann Intern Med       Date:  1982-03       Impact factor: 25.391

  10 in total
  14 in total

1.  Enalapril and metoprolol in diabetic nephropathy.

Authors: 
Journal:  BMJ       Date:  1990-05-26

2.  Coronary flow reserve and the J curve.

Authors:  J M Cruickshank
Journal:  BMJ       Date:  1989-02-18

Review 3.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 4.  Non-steroidal anti-inflammatory drugs and angiotensin converting enzyme inhibitors: a commonly prescribed combination with variable effects on renal function.

Authors:  N D Sturrock; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

Review 5.  ACE inhibitors. Drug interactions of clinical significance.

Authors:  C Mignat; T Unger
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

6.  Acute renal failure with ACE inhibition in aortic coarctation.

Authors:  P A Woodmansey; W W Yeo; P R Jackson; L E Ramsay
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

Review 7.  The J-curve in hypertension.

Authors:  John Cruickshank
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

Review 8.  Angiotensin converting enzyme (ACE) inhibitors and renal function. A review of the current status.

Authors:  A L Kamper
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

9.  Perindopril postmarketing surveillance: a 12 month study in 47,351 hypertensive patients.

Authors:  C Speirs; F Wagniart; L Poggi
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

Review 10.  Current approaches to renovascular hypertension.

Authors:  Stephen C Textor
Journal:  Med Clin North Am       Date:  2009-05       Impact factor: 5.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.